A share price of Halozyme Therapeutics Inc [HALO] is currently trading at $55.8, up 2.91%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HALO shares have gain 7.27% over the last week, with a monthly amount glided 4.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on May 14, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $62 for it. Previously, Leerink Partners downgraded its rating to Underperform on May 13, 2025, and kept the price target unchanged to $47. On October 07, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $62 on the stock. JP Morgan downgraded its rating to a Neutral and increased its price target to $57 on September 19, 2024. Piper Sandler downgraded its rating to a Neutral and raised its price target to $51 on June 07, 2024. TD Cowen started tracking with a Outperform rating for this stock on February 29, 2024, and assigned it a price target of $54. In a note dated July 24, 2023, H.C. Wainwright initiated an Buy rating and provided a target price of $61 on this stock.
Halozyme Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $42.01 and $70.50. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $55.8 at the most recent close of the market. An investor can expect a potential return of 11.11% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Trailing Twelve Months sales for Halozyme Therapeutics Inc [NASDAQ:HALO] were 1.08B which represents 35.22% growth. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.55%, Pretax Profit Margin comes in at 0.56%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.22 and Total Capital is 0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.56 points at the first support level, and at 53.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.63, and for the 2nd resistance point, it is at 57.45.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Halozyme Therapeutics Inc [NASDAQ:HALO] is 8.39. Also, the Quick Ratio is 7.30, while the Cash Ratio stands at 1.17. Considering the valuation of this stock, the price to sales ratio is 6.34, the price to book ratio is 14.25 and price to earnings (TTM) ratio is 14.80.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Jun 24 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Jun 20 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Jun 23 ’25.
